At its meeting on 22 July 2024 , the Transparency Council adopted position No. 73/2024 on the evaluation of the drug Fintepla (fenfluramine) under the B.154.FM drug program. “Treatment of patients with Lennox-Gastaut Syndrome or Dravet Syndrome (ICD-10: G40.4).”